Prevention of migraine with olmesartan in patients with hypertension/prehypertension

Headache
James A CharlesLawrence H Byrd

Abstract

To explore the effects of olmesartan on frequency and severity of migraine attacks in patients with comorbid hypertension and prehypertension. A randomized, double-blind, placebo-controlled, crossover study with a total of 60 patients has demonstrated the efficacy and safety of the angiotensin II receptor blocker candesartan in migraine prophylaxis. We study the potential efficacy and tolerability of olmesartan in preventing migraine in patients with hypertension and prehypertension. Twenty-four adults, aged 27 through 76, with either hypertension or prehypertension, were included in this open-label study. Participants suffered from migraines (diagnosed according to International Headache Society classifications) for at least 3 months. Patients were treated with 10 to 40 mg of olmesartan per various observational periods of at least 3 months. Frequency and severity were recorded by office visits or by telephonic interview. Patients reported an 82.5% average reduction in the frequency of migraine attacks. Patients also experienced a 45% average reduction in the severity of migraine attacks measured on a numeric pain scale of 1 to 10. The only undesired effect was dizziness or presyncope. No serious adverse events occurred and no...Continue Reading

References

Dec 31, 2002·JAMA : the Journal of the American Medical Association·Erling TronvikGunnar Bovim
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee

❮ Previous
Next ❯

Citations

Jul 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Suneet MehrotraAntoinette MaassenVanDenBrink
Jan 30, 2008·Der Schmerz·V M ReinischA Straube
Jul 17, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Elio Agostoni, Angelo Aliprandi
Mar 8, 2008·Current Treatment Options in Neurology·Markus SchürksPeter Goadsby
Oct 12, 2010·Future Cardiology·Rui Andre Providencia
Apr 15, 2014·Current Pain and Headache Reports·Erling Tronvik, Lars Jacob Stovner
Sep 23, 2009·Expert Review of Neurotherapeutics·Chad A Whyte, Stewart J Tepper
Jun 24, 2008·Expert Opinion on Pharmacotherapy·André C SchmidtReinhold Kreutz
Jul 5, 2008·The Journal of Headache and Pain·Simona SaccoAntonio Carolei
Mar 28, 2009·Regulatory Peptides·Hans ImbodenJuan M Saavedra
Jan 31, 2009·Headache·Markus SchürksTobias Kurth
Sep 1, 2006·Headache·Yasuo Iwasaki, Ken Ikeda
Feb 18, 2010·Pain Practice : the Official Journal of World Institute of Pain·Yaprak SeçilMustafa Başoğlu
Apr 29, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Caterina DiscoGiorgio Zanchin
Jun 11, 2016·Journal of Stroke·Mi Ji LeeChin-Sang Chung
Jun 20, 2012·Cephalalgia : an International Journal of Headache·Simona SaccoAntonio Carolei
Aug 15, 2014·Expert Review of Neurotherapeutics·Patrizia RipaSimona Sacco
Jan 30, 2020·Protein and Peptide Letters·Karina Lúcia Moreira SassiAntonio Lucio Teixeira
Feb 23, 2017·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Ken IkedaYasuo Iwasaki
Sep 4, 2020·Headache·Laís Bhering MartinsAntonio Lúcio Teixeira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Canadian Journal of Physiology and Pharmacology
J O DostrovskyK Kawakita
The Journal of Comparative Neurology
Rami Burstein, Moshe Jakubowski
Brain Research. Molecular Brain Research
O BaltatuM Bader
© 2022 Meta ULC. All rights reserved